![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Over the last few years surgery on patients with abdominal malignancies has become more aggressive but the majority of patients present locoregional recurrence as peritoneal dissemination. Cytoreductive surgery followed by intraperitoneal chemohyperthermic perfusion (ICHP) has been described for treatment and prevention of locoregional cancer spread from various origins. This paper reports our study of the pharmacokinetics of mitomycin C (MMC) administered by intraperitoneal chemohyperthermic perfusion (ICHP) in patients with peritoneal carcinomatosis. 28 patients received MMC 20 mg/m2 intraperitoneally as a perfusion over 60 min. MMC was determined in perfusate, plasma and urine samples with a UVHPLC method. A compartmental model was used to fit the drug concentrations in plasma and perfusate.
Our results showed a mean maximum plasma concentration (Cmax) of 0.14±0.086 μg/ml with a peak time (Tmax) of 48..7 ± 5.61 min. The mean area under the curve (AUC) and terminal half-life (t1/2 ) were 15.8 ± 9.8 mg x min / L and 83.7 ± 31.74 min respectively. Clearance (CL) was estimated by fitting the data by a compartmental model and the mean value was 72 ± 66 L/h. The percent of the dose absorbed was very variable and ranged between 14 and 57% (mean 37 ± 14%). The mean percentage of dose recovered unchanged in the urine during 24 hours was 7.21 ± 3.73%.
We conclude that ICHP in patients with peritoneal surface malignancies seems to have clinical value since it gives high peritoneal and tumor MMC concentrations with limited systemic exposure and toxicity.